版本:
中国

BRIEF-Clearside Biomedical provides update on diabetic macular edema trial

April 20 Clearside Biomedical Inc

* Clearside biomedical, inc. Announces completion of patient enrollment in phase 1/2 open label clinical trial of cls-ta in diabetic macular edema

* Currently expects to report preliminary results from exploratory clinical trial of cls-ta in second half of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐